OakChart

Coya Therapeutics Inc

COYAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.21+0.05 (1.58%)
2026-11-12 00:59 CET
Market cap
74.13 USD m
Revenue, TTM
4.69 USD m
Net income, TTM
-30.17 USD m
Free cash flow, TTM
-21.83 USD m
EPS diluted, TTM
-1.33
P/E
-
Compare

Price

COYA against its 20, 50 and 200-day averages
2050200beatmiss
3.004.005.006.00288K575KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COYAclose 3.2120-day 3.6950-day 4.34200-day 4.593.2152w low

51.5% under the 52-week high of 6.62 on 1 Dec 2025. 52-week low 2.72 on 5 Nov 2026. Last 15 sessions, 62.9% high to low

Volume 0.62× normal · the line is the 50-bar volume average

Profile

COYA
52-week range, 13% of the way up
2.726.62

Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing proprietary new therapies to enhance the function of regulatory T cells. Its pipeline includes Treg Modifying Biologics, Allogeneic Treg-Derived Exosomes, and Autologous Treg Cell Therapy. The company was founded by Howard Berman in 2020 and is headquartered in Houston, TX.

Employees8
IPODec 29, 2022
Beta0.75
ATR, 14d0.33
Rel volume0.62
Short float7.05%
Insider own14.69%
Inst own33.02%

Snapshot

6 groups

Valuation

Index-
Market Cap75.30M
Enterprise Value39.50M
Income-30.17M
Sales4.69M
Book/sh1.43
Cash/sh1.53
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPODec 29, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S16.06
P/B2.24
P/C2.10
P/FCF-
EV/EBITDA-
EV/Sales8.42
Quick Ratio7.24
Current Ratio7.24
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.33
EPS next Y-1.47
EPS next Q-0.40
EPS this Y-9.11%
EPS next Y-5.72%
EPS next 5Y5.40%
EPS past 3/5Y-1.01% -75.69%
Sales past 3/5Y- -
EPS Y/Y TTM-20.34%
Sales Y/Y TTM17.59%
EPS Q/Q-258.07%
Sales Q/Q-93.43%
EarningsNov 10 BMO
EPS/Sales Surpr.-32.35% 112.82%

Ownership

Insider Own14.69%
Insider Trans0.00%
Inst Own33.02%
Inst Trans-0.25%
ROA-84.56%
ROE-99.16%
ROIC-89.88%
Gross Margin99.67%
Oper. Margin-636.77%
Profit Margin-643.45%
SMA20-13.08%
SMA50-26.12%
SMA200-30.00%
Trades-

Technical

Shs Outstand23.46M
Shs Float20.01M
Short Float7.05%
Short Ratio9.76
Short Interest1.41M
52W High6.62 -51.51%
52W Low2.72 18.01%
Volatility13.17% 9.75%
ATR (14)0.33
RSI (14)35.24
Beta0.75
Rel Volume0.62
Avg Volume144.53K
Volume89,971

Performance

Perf Week4.22%
Perf Month-28.27%
Perf Quarter-31.26%
Perf Half Y-29.30%
Perf YTD-44.66%
Perf Year-46.59%
Perf 3Y-36.44%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price15.21
Prev Close3.16
Price3.21
Change %1.58%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Jun 05, 2026InitiatedRRoth CapitalBuy$12+273.8%
Jul 09, 2025InitiatedLLake StreetBuy$16+398.4%
Dec 04, 2024InitiatedDD. Boral CapitalBuy$15+367.3%

Peers

Mkt cap
TickerCompanyMkt cap
CLNNClene Inc60.40M
MNOVMedicinova Inc69.40M
PMNProMIS Neurosciences Inc33.72M
ALECAlector Inc391.55M
INMBINmune Bio Inc34.05M
NRSNNeuroSense Therapeutics Ltd3.38M
DNLIDenali Therapeutics Inc3.16B
CGTXCognition Therapeutics Inc64.42M
AMLXAmylyx Pharmaceuticals Inc4.09B
BIIBBiogen Inc37.46B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFMCU.S. Micro Cap Portfolio ETF Class SharesAUM: 212.10M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
DXUVUS Vector Equity Portfolio ETF Class SharesAUM: 665.71M
DFACU.S. Core Equity 2 Portfolio-ETF Class SharesAUM: 49.14B
DCORUS Core Equity 1 Portfolio ETF Class SharesAUM: 3.65B
DFSUDimensional US Sustainability Core 1 ETFAUM: 2.38B

News

latest 14 of 198

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.450-0.340-0.4500.230.117
2026Q22026-08-11-0.280-0.346-0.2830.190.137
2026Q12026-05-12-0.320-0.416-0.3180.290.157
2025Q42026-03-16-0.340-0.273-0.2733.982.257
2025Q32025-11-12-0.130-0.233-0.1263.563.707
2025Q22025-08-12-0.360-0.419-0.3640.160.787
2025Q12025-05-13-0.440-0.194-0.4370.292.634
2024Q42025-03-18-0.180-0.275-0.1750.200.106
2024Q32024-11-06-0.260-0.362-0.2640.001.885
2024Q22024-08-12-0.190-0.170-0.1943.412.753
2024Q12024-05-09-0.350-0.300-0.3490.11-1
2023Q42024-03-190.1400.2570.0886.007.501
2023Q32023-11-08-0.340-0.352-0.344--2
2023Q22023-08-08-0.310-0.320-0.311--2
2023Q12023-05-10-0.280-0.430-0.275--1
2022Q42023-03-29-0.470--0.312---

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-4.730-1.820-1.2310.000.00
2023FY-0.790-0.874-0.7866.004.05
2024FY-0.980-1.095-0.9773.553.67
2025FY-1.270-1.194-1.2707.955.92
2026FY--1.386--1.04
2027FY--1.465--5.04
2028FY--1.075--19.55
2029FY--2.280--1.00
2030FY--2.460--1.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-105000.660.003.00
2026Q4S2026-08-205000.660.003.00
2026Q4S2026-08-117001.900.0010.00
2026Q4S2026-06-047001.900.0010.00
2026Q4S2026-05-306002.220.0010.00
2026Q4S2026-05-156112.220.0010.00
2026Q4S2026-05-125112.660.0010.00
2026Q4S2026-03-185112.660.0010.00
2026Q4S2026-03-166112.220.0010.00
2026Q4S2026-01-305000.130.000.40
2026Q4S2026-01-264000.100.000.40
2026Q4S2025-11-124010.100.000.40
2026Q4S2025-11-114000.230.000.90
2026Q4S2025-11-104000.230.000.90

Estimate history

EPS, annual-0.076-0.505-1.231-0.786-0.977-1.269-1.3266
Period202020212022202320242025TTM
EPS, quarterly-0.264-0.175-0.437-0.364-0.126-0.273-0.318-0.283-0.453
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0006.0023.5547.9464.69
Period202020212022202320242025TTM
Sales, quarterly00.0020.2580.1643.5643.960.2510.2440.234
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual9.6799.6799.94814.40516.70720.93423.458
Period202020212022202320242025MRQ
Shares, quarterly15.22116.70716.72516.72516.74320.93423.45723.45823.458
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue4.697.953.556.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.030.030.030.030.020.00
Gross Profit4.677.923.535.97-0.03-0.020.00
Selling, General and Administrative Excl. Other34.5328.1820.7513.349.264.850.69
Research and Development22.6416.7311.875.504.412.540.25
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-29.86-20.27-17.22-7.36-9.29-4.87-0.69
Interest Expense0.000.000.00--0.000.04
Unusual Expense1.812.290.030.543.020.000.00
Net Income Before Taxes-30.17-21.22-15.60-7.26-12.24-4.89-0.73
Income Taxes0.000.00-0.720.720.000.000.00
Consolidated Net Income-30.17-21.23-14.88-7.99-12.24-4.89-0.73
Net Income From Continuing Operations-30.17-21.23-14.88-7.99-12.24-4.89-0.73
Net Income-30.17-21.23-14.88-7.99-12.24-4.89-0.73
EPS (Recurring)-1.23-1.17-0.98-0.75-1.02-0.51-0.08
EPS (Basic, Before Extraordinaries)-1.33-1.27-0.98-0.79-1.23-0.51-0.08
EPS (Diluted)-1.33-1.27-0.98-0.79-1.23-0.51-0.08
EBITDA-29.84-20.24-17.20-7.33-9.26-4.85-0.69
Non-Operating Income (Expense)1.501.331.650.640.06-0.020.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense3.593.392.100.690.210.230.00
Price To Sales Ratio25.0612.2124.5712.55---
Gross Margin99.6799.6699.2399.54---
Operating Margin-636.77-255.05-484.65-122.62---
Net Margin-643.45-267.14-418.70-133.08---
Shares Outstanding23.4620.9316.7114.419.959.689.68
Market Capitalization74.1374.1395.7373.7145.8645.86-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.230.240.253.963.560.160.260.00
Cost of Goods Sold Incl. D&A0.000.000.000.010.010.010.010.01
Gross Profit0.230.240.253.953.560.160.25-0.00
Selling, General and Administrative Excl. Other11.167.297.888.215.476.577.934.08
Research and Development8.575.034.104.942.923.665.211.94
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.93-7.05-7.63-4.26-1.92-6.41-7.68-4.08
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.020.000.011.770.520.000.00-
Net Income Before Taxes-10.62-6.64-7.21-5.71-2.12-6.09-7.31-3.64
Income Taxes0.000.000.000.000.000.000.00-0.72
Consolidated Net Income-10.62-6.64-7.21-5.71-2.12-6.09-7.31-2.92
Net Income From Continuing Operations-10.62-6.64-7.21-5.71-2.12-6.09-7.31-2.92
Net Income-10.62-6.64-7.21-5.71-2.12-6.09-7.31-2.92
EPS (Recurring)-0.45-0.28-0.32-0.21-0.10-0.36-0.44-0.17
EPS (Basic, Before Extraordinaries)-0.45-0.28-0.32-0.27-0.13-0.36-0.44-0.17
EPS (Diluted)-0.45-0.28-0.32-0.27-0.13-0.36-0.44-0.17
EBITDA-10.92-7.04-7.63-4.25-1.91-6.41-7.67-4.07
Non-Operating Income (Expense)0.330.410.430.330.320.320.370.44
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.910.751.730.201.071.041.080.62
Price To Sales Ratio25.0617.1111.2415.2823.92227.1129.3626.94
Gross Margin98.8098.8598.8899.8399.8195.8297.35-250.41
Operating Margin-4,666.29-2,890.45-3,038.15-107.51-53.78-3,920.47-2,976.89-209,031.51
Net Margin-4,534.90-2,723.44-2,869.63-144.16-59.36-3,725.17-2,833.35-149,373.77
Shares Outstanding23.4623.4623.4620.9316.7416.7216.7216.71
Market Capitalization74.13137.2292.42121.3695.3396.17108.2195.73

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments46.8238.3432.635.934.348.72
Short Term Receivables0.000.737.500.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.125.241.071.250.240.03
Total Current Assets49.9444.3141.207.184.588.75
Net Property, Plant & Equipment0.010.040.070.090.120.00
Total Investments and Advances0.000.000.000.000.000.00
Long-Term Note Receivable-0.000.01---
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.001.120.090.00
Total Assets49.9544.3541.278.404.798.75
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable1.061.591.161.820.860.45
Income Tax Payable-0.000.72---
Other Current Liabilities4.812.243.172.010.290.00
Total Current Liabilities5.873.825.053.821.150.45
Long Term Debt0.000.000.0012.970.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities1.050.950.570.000.000.00
Total Liabilities6.924.775.6316.791.150.45
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.008.798.798.79
Common Equity43.0339.5835.65-17.19-5.15-0.49
Total Shareholders Equity43.0339.5835.65-8.393.648.30
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity43.0339.5835.65-8.393.648.30
Total Liabilities & Stockholders Equity49.9544.3541.278.404.798.75
Book Value Per Share2.062.372.47-1.73-0.53-0.05
Tangible Book Value Per Share2.062.372.47-1.73-0.53-0.05
Full-Time Employees8886--
Price to Book Ratio2.212.727.31-3.24-3.24-
Return on Assets-45.02-34.76-32.16-185.70-72.25-
Return on Equity-51.39-39.56-58.62--81.90-
Return on Invested Capital-49.33-37.60-22.41-267.82-134.25-8.83
Quick Ratio8.5011.598.151.883.9919.57
Current Ratio8.5011.598.151.883.9919.57

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-30.17-21.23-14.88-7.99-12.24-4.89-0.73
Depreciation0.020.030.030.030.030.020.00
Other Funds (Non Cash)6.966.582.691.424.230.230.26
Funds from Operations-23.19-14.62-12.16-6.55-7.99-4.64-0.47
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital1.373.881.88-4.640.750.740.08
Cash from Operating Activities-21.83-10.74-10.29-11.19-7.24-3.90-0.39
Capital Expenditures-1.56-1.16-0.030.000.00-0.140.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.00-0.54-0.530.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-1.56-1.16-0.03-0.54-0.53-0.140.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock31.3020.3916.0238.430.000.009.11
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock31.3020.3916.0238.430.000.009.11
Proceedsfrom Stock Options20.3520.3513.8738.340.000.009.11
Issuance or Reduction of Debt, Net0.000.000.000.009.470.000.00
Change in Long Term Debt0.000.000.000.009.470.000.00
Issuance of Long Term Debt0.000.000.000.009.470.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.240.000.010.00-0.11-0.340.00
Other Financing Activities Uses-0.240.000.000.00-0.11-0.340.00
Cash from Financing Activities31.0620.3916.0338.439.36-0.349.11
Net Change in Cash7.678.485.7126.691.59-4.388.72
Free Cash Flow-21.83-10.74-10.29-11.19-7.24-4.04-0.39
Preferred Dividends (Cash Flow)-0.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments35.8043.1850.7246.8228.1329.76
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.273.882.543.123.893.67
Total Current Assets39.0747.0653.2649.9432.0233.43
Net Property, Plant & Equipment0.000.010.010.010.020.02
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets--0.000.000.000.00
Other Assets0.240.240.000.000.000.00
Total Assets39.3247.3153.2749.9532.0433.45
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable2.451.090.951.061.110.93
Other Current Liabilities2.942.432.604.812.563.57
Total Current Liabilities5.393.513.555.873.674.50
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.350.520.751.051.090.64
Total Liabilities5.754.034.306.924.765.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity33.5743.2848.9743.0327.2828.31
Total Shareholders Equity33.5743.2848.9743.0327.2828.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity33.5743.2848.9743.0327.2828.31
Total Liabilities & Stockholders Equity39.3247.3153.2749.9532.0433.45
Book Value Per Share1.431.842.092.061.631.69
Tangible Book Value Per Share1.431.842.092.061.631.69
Full-Time Employees---8--
Price to Book Ratio2.212.801.923.563.372.88
Return on Assets-84.56-53.66-46.09-45.02-54.54-55.43
Return on Equity-99.16-60.54-51.31-51.39-62.18-63.99
Return on Invested Capital-31.63-15.34-14.72-13.27-7.75-21.53
Quick Ratio7.2413.4015.028.508.737.43
Current Ratio7.2413.4015.028.508.737.43

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-10.62-6.64-7.21-5.71-2.12-6.09
Depreciation0.000.000.000.010.010.01
Other Funds (Non Cash)0.930.952.212.881.591.04
Funds from Operations-9.68-5.69-5.00-2.82-0.52-5.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.45-1.69-1.211.82-0.61-0.72
Cash from Operating Activities-7.24-7.38-6.21-1.01-1.13-5.77
Capital Expenditures-0.02-0.00-0.89-0.65-0.520.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.02-0.00-0.89-0.65-0.520.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.12-0.1711.0020.350.020.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.12-0.1711.0020.350.020.00
Proceedsfrom Stock Options0.12-0.120.0020.350.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.240.000.000.000.000.00
Other Financing Activities Uses-0.240.000.000.000.000.00
Cash from Financing Activities-0.12-0.1711.0020.350.020.00
Net Change in Cash-7.38-7.543.9018.69-1.63-5.77
Free Cash Flow-7.24-7.38-6.21-1.01-1.13-5.77

Revenue breakdown

Pharmaceutical Preparations2024: 3.55M 2025: 7.95M
United States2024: 3.55M 2025: 7.95M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.05%1.4M20.0M131.63K
2026-10-156.27%1.3M20.0M147.37K
2026-09-305.95%1.2M20.0M171.69K
2026-09-155.94%1.2M20.0M183.68K
2026-08-315.43%1.1M20.0M191.99K
2026-08-145.28%1.1M20.0M195.74K
2026-07-315.36%1.1M20.0M207.79K
2026-07-155.24%1.0M20.0M196.54K
2026-06-304.57%0.9M20.0M172.07K
2026-06-154.95%1.0M20.0M158.77K
2026-05-294.60%0.9M20.0M149.92K
2026-05-154.09%0.8M20.0M150.38K
2026-04-304.13%0.8M20.0M139.27K
2026-04-153.86%0.8M20.0M158.84K
2026-03-313.99%0.9M22.1M199.85K
2026-03-133.76%0.8M22.1M211.07K
2026-02-274.28%0.8M19.7M221.28K
2026-02-134.27%0.8M19.7M235.33K
2026-01-304.46%0.9M19.7M237.19K
2026-01-154.28%0.8M19.7M254.23K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.004.903.180.00010.000.000.880-0.0090.001
call5.000.004.900.030.0002500.000.422-0.0540.002
call7.500.001.750.253.7064.000.000.132-0.0210.001
call10.000.004.900.0013.3430.000.000.702-0.1330.002
put2.500.000.050.0523.01910.000.00-0.030-0.0430.000
put5.001.152.302.454.9170.000.00-0.578-0.0540.002
put7.502.006.502.8016.1360.000.00-0.277-0.1220.002
put10.004.509.000.0017.0400.000.00-0.287-0.1330.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-058-KCurrent report2026-10-05SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-078-K/A2026-03-29SEC
2026-07-27SCHEDULE 13G/ASEC
2026-06-258-KCurrent report2026-06-25SEC
2026-05-13ARSAnnual report to security holders. 2025-12-31SEC
2026-05-13DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-05-13DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-25SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-05-12424B5SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-094Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-04-093Initial statement of beneficial ownership of securities2026-04-01SEC
2026-04-028-KCurrent report2026-03-29SEC
2026-03-20EFFECTEffectiveness filing by commission orderSEC
2026-03-20424B3SEC
2026-03-19CORRESPSEC
2026-03-19UPLOADUpload SubmissionSEC
2026-03-16S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-03-1610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-168-KCurrent report2026-03-16SEC
2026-03-12SCHEDULE 13GSEC
2026-01-308-KCurrent report2026-01-29SEC
2026-01-30SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DME Capital Management, LP9.96%
VANGUARD CAPITAL MANAGEMENT LLC3.59%
Alyeska Investment Group, L.P.3.41%
AIGH Capital Management LLC2.69%
CM Management, LLC1.71%
PRIVATE MANAGEMENT GROUP INC1.62%
MARSHALL WACE, LLP1.06%
GEODE CAPITAL MANAGEMENT, LLC0.90%
RENAISSANCE TECHNOLOGIES LLC0.82%
Prosight Management, LP0.72%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.56%
VANGUARD EXTENDED MARKET INDEX FUND0.94%
Fidelity Extended Market Index Fund0.47%
Dimensional U.S. Small Cap ETF0.32%
iShares Micro-Cap ETF0.28%
U.S. MICRO CAP PORTFOLIO0.16%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.13%
U.S. SMALL CAP PORTFOLIO0.06%
Avantis U.S. Small Cap Equity ETF0.05%

OakChart. COYA. Cached 15 minutes.

Some panels did not load: insider.